Castle Biosciences (NASDAQ:CSTL) updated its FY 2021 earnings guidance on Tuesday. The company provided earnings per share guidance of $- for the period. The company issued revenue guidance of $80 million-83 million, compared to the consensus revenue estimate of $79.84 million.
Several brokerages have weighed in on CSTL. Zacks Investment Research raised Castle Biosciences from a sell rating to a hold rating in a report on Monday, May 10th. Robert W. Baird reissued a buy rating and set a $73.00 price objective on shares of Castle Biosciences in a report on Thursday, May 13th. Finally, Lake Street Capital began coverage on Castle Biosciences in a report on Friday, April 30th. They set a buy rating and a $94.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Castle Biosciences currently has a consensus rating of Buy and an average target price of $80.29.
Shares of CSTL traded down $0.86 on Friday, hitting $70.36. The company’s stock had a trading volume of 10,542 shares, compared to its average volume of 289,573. The business has a fifty day moving average of $63.70. Castle Biosciences has a fifty-two week low of $34.72 and a fifty-two week high of $107.69. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of -100.31 and a beta of 0.42.
In other Castle Biosciences news, Director David S. Kabakoff sold 10,000 shares of the stock in a transaction on Friday, March 19th. The stock was sold at an average price of $66.17, for a total transaction of $661,700.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David S. Kabakoff sold 120,000 shares of the stock in a transaction on Tuesday, March 16th. The stock was sold at an average price of $63.74, for a total value of $7,648,800.00. The disclosure for this sale can be found here. In the last three months, insiders sold 374,137 shares of company stock valued at $24,818,071. 15.40% of the stock is currently owned by insiders.
Castle Biosciences Company Profile
Castle Biosciences, Inc, a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue.
Recommended Story: What is the Coverage Ratio?
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.